Cumberland Pharmaceuticals and Tabuk Pharmaceutical Manufacturing Company announced the launch of Cumberland's Vibativ (telavancin) injection in Saudi Arabia. This launch follows an agreement granting Tabuk exclusive rights to register and promote the product in Saudi Arabia and other Middle Eastern countries.
Vibativ is an FDA-approved injectable anti-infective designed to treat serious bacterial infections, including hospital-acquired and ventilator-associated pneumonia, and serious skin infections caused by Gram-positive bacteria, such as MRSA. It is administered once-daily and does not require therapeutic drug monitoring.
The launch in Saudi Arabia expands the international reach of Vibativ, addressing the global concern about multidrug-resistant organisms in a new market. This strategic expansion is expected to provide a powerful new tool for physicians in the region to combat difficult-to-treat infections.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.